Skip to main content
Fig. 3 | Acta Neuropathologica Communications

Fig. 3

From: Erythrocytic α-synuclein contained in microvesicles regulates astrocytic glutamate homeostasis: a new perspective on Parkinson’s disease pathogenesis

Fig. 3

Astrocytes can take up RBC-EVs preferentially at endfeet in vivo. a-d Representative images of brain slices of striatum following peripheral injection of DiI-EVs and labeling with GFAP (marker for astrocytes) and Kir4.1 (marker for astrocytic endfeet). Note that DiI-EV co-localized with GFAP (a-b) and Kir4.1 (c-d) (Scale bar, 10 μm). e Analysis of the percentage of DiI-EVs colocalizing with MAP 2, Kir4.1 or IBA1 labeled cells in brain slices of LPS pre-administered WT mice or A53T mice (n = 5 for LPS pre-administered WT mice; n = 4 for A53T mice). f-h Graphs show analysis of the percentage of DiI-EVs colocalizing with MAP 2 (marker for neurons), Kir4.1 (marker for astrocytic endfeet) or IBA1 (marker for microglia) labeled cells in cortex (CTX, (f)), striatum (STR, (g)) and midbrain (MIDB, (h)). Note that increased percentage of DiI-EVs were colocalized with Kir4.1 at striatum in A53T mice compared with the LPS pre-administered WT mice (g; means + S.E.M; n ≥ 4; **p < 0.01 by One-way ANOVA test)

Back to article page
\